Haiying Zhu

TL;DR: In this patient, viscerotropic disease was not due to the impaired magnitude of adaptive immunity but instead to anomalies in the innate immune system and a possible disruption of the CCR5-RANTES axis.

TL;DR: It is found that during transmission of HIV-1 subtype B, as for other subtypes reported in the past, viral populations in recipients undergo substantial genetic bottlenecks, as well as weak evidence for a propensity to replicate viruses with shorter variable loops and fewer potential N-linked glycosylation sites.

TL;DR: Head-to-head evaluation of different SARS-CoV-2 neutralization platforms could facilitate comparisons across studies and laboratories, and high concordance between the outcomes of cell-based assays with live and pseudotyped virions enables valid cross-study comparison using these platforms.

TL;DR: In this paper, the authors investigated the performance characteristics of the recently FDA-authorized semiquantitative anti-spike protein AdviseDx SARS-CoV-2 IgG II assay compared to the FDA authorized anti-nucleocapsid protein Abbott Architect SARS CoV2 IgG, Roche Elecsys anti-SARS-coV2-S, EuroImmun anti SARSCoV2 enzyme-linked immunosorbent assay (ELISA), and GenScript surrogate virus neutralization assays and examined the humoral response

TL;DR: It is suggested that ART inhibits HIV‐1 replication in CD4+ T cells more than in blood monocytes and that better treatments to combat HIV‐ 1 in monocytes/macrophages may be needed for a more complete suppression of HIV replication.